SCYNEXIS

Scynexis

Biotechnology, 1 Evertrust PLZ Ste 1301, Jersey City, New Jersey, 07302, United States, 11-50 Employees

scynexis.com

  • twitter
  • LinkedIn

phone no Phone Number: 20********

Who is SCYNEXIS

At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insid...

Read More

map
  • 1 Evertrust PLZ Ste 1301, Jersey City, New Jersey, 07302, United States Headquarters: 1 Evertrust PLZ Ste 1301, Jersey City, New Jersey, 07302, United States
  • 2000 Date Founded: 2000
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies
  • David Angulo CEO:   David Angulo

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 999990 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SCYNEXIS

SCYNEXIS Org Chart and Mapping

David Angulo

Chief Executive Officer

Employees

Tom Chen

Independent Consultant

David Kriesel

Executive Director, Medical Sciences

James Davis

Associate Director, Program Management

Jitka Shavel

Director, Manufacturing and Supply Chain

Jill Shapiro

Women’s Health Pharmaceutical Sales Representative

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SCYNEXIS

Answer: SCYNEXIS's headquarters are located at 1 Evertrust PLZ Ste 1301, Jersey City, New Jersey, 07302, United States

Answer: SCYNEXIS's phone number is 20********

Answer: SCYNEXIS's official website is https://scynexis.com

Answer: SCYNEXIS's revenue is $50 Million to $100 Million

Answer: SCYNEXIS's SIC: 2834

Answer: SCYNEXIS's NAICS: 999990

Answer: SCYNEXIS has 11-50 employees

Answer: SCYNEXIS is in Biotechnology

Answer: SCYNEXIS contact info: Phone number: 20******** Website: https://scynexis.com

Answer: At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access